AVBP vs AZTR

ArriVent BioPharma, Inc. vs Azitra Inc — Valuation Comparison 2026

AVBP

Biotechnology
ArriVent BioPharma, Inc.
Quality
3.6
out of 10
Value Trap
12
SAFE
Price
$26.97
Last close
Models
7/13
Active
VS

AZTR

Biotechnology
Azitra Inc
Quality
4.3
out of 10
Value Trap
44
WARN
Price
$0.21
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType AVBP Fair ValueAVBP Upside AZTR Fair ValueAZTR Upside
Bayesian DCF Intrinsic $7.90 -70.7% $0.38 +87.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.59 -98.0% $0.04 -81.5%
Dynamic NAV Asset-Based $6.38 -76.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVBP vs AZTR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVBP vs AZTR — Which Stock Is More Undervalued?

AZTR scores higher with a 4.3/10 quality rating vs AVBP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ArriVent BioPharma, Inc. (AVBP) and Azitra Inc (AZTR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVBP currently trades at $26.97 with a QOC of 3.6/10, while AZTR trades at $0.21 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).